moatshark My

All holdings

Embecta

EMBC

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$14.1m
Combined value at quarter end
Last quarter
1 bought
1 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q2 ’26 end
$3.26
-63.1% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+12.8%Q3 ’24
+46.5%Q4 ’24
-38.3%Q1 ’25
-24.0%Q2 ’25
+45.6%Q3 ’25
-15.8%Q4 ’25
-25.6%Q1 ’26
-63.1%Q2 ’26
Q3 ’24: +12.8%; Q4 ’24: +46.5%; Q1 ’25: -38.3%; Q2 ’25: -24.0%; Q3 ’25: +45.6%; Q4 ’25: -15.8%; Q1 ’26: -25.6%; Q2 ’26: -63.1%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

2Q4 ’23
2Q1 ’24
2Q2 ’24
2Q3 ’24
2Q4 ’24
2Q1 ’25
3Q2 ’25
3Q3 ’25
3Q4 ’25
2Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 2; Q1 ’24: 2; Q2 ’24: 2; Q3 ’24: 2; Q4 ’24: 2; Q1 ’25: 2; Q2 ’25: 3; Q3 ’25: 3; Q4 ’25: 3; Q1 ’26: 2; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Embecta.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Embecta
Yacktman Asset Management0.2%$14.1m$14.1mAdded +18%17 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Embecta
Bought or soldFiling
4 Sep 2026Morris Milton MayoDirector▼ Sold6,293$5.88$37kForm 4
12 Aug 2026Hombach Robert J.Director▲ Bought45,000$4.97$224kForm 4
12 Aug 2026Kurdikar DevdattPresident and CEO▲ Bought30,000$4.70$141kForm 4
12 Aug 2026Mann Jeffrey ZPres, Pharm Svc&Prod Mgmt, CLO▲ Bought20,000$4.99$100kForm 4
12 Aug 2026Elguicze JacobSVP and CFO▲ Bought20,000$4.67$93kForm 4

About the company

Sector
Health care · Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Financial year ends
30 September
Shares outstanding
57m at 31 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$1.1bnSep ’20
$1.2bnSep ’21
$1.1bnSep ’22
$1.1bnSep ’23
$1.1bnSep ’24
$1.1bnSep ’25
Sep ’20: $1.1bn; Sep ’21: $1.2bn; Sep ’22: $1.1bn; Sep ’23: $1.1bn; Sep ’24: $1.1bn; Sep ’25: $1.1bn
Embecta revenue and net income by year
YearRevenueNet income
Year to Sep 2025$1.1bn$95.4m
Year to Sep 2024$1.1bn$78.3m
Year to Sep 2023$1.1bn$70.4m
Year to Sep 2022$1.1bn$224m
Year to Sep 2021$1.2bn$415m
Year to Sep 2020$1.1bn$428m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

Sold out last quarter

In fund portfolios

US-registered funds run by these managers that hold Embecta, from their latest N-PORT filings.

Funds holding Embecta
AMG Yacktman FundYacktman Asset Management0.2%$11.4m30 Jun 2026